Molecule2 diseases

MYD88

TLR signalling adaptor

Expression change
L265P in ~30%
Evidence level
moderate
Targeted by
Ibrutinib (indirect)

Expression across diseases

DiseaseRoleExpressionEvidence
Schnitzler SyndromeTLR signalling adaptorL265P in ~30%moderate
Waldenström's MacroglobulinemiaCentral oncogenic driver (TLR/IL-1R adaptor)L265P gain-of-function in >90%established

Role in pathogenesis

MYD88 L265P is found in ~30% of Schnitzler patients and >90% of Waldenström's cases. Drives NF-κB activation.

Targeting drugs (1)

DrugMechanismResponse rateLine
IbrutinibBTK inhibitorComplete in case reportsAlternative

Sources (2)

DetailsPathak S et al. (2019) MYD88 L265P in 30% of Schnitzler patientsDOI ↗
DetailsVan Leersum FS et al. (2019) Shared MYD88/NF-κB mechanism hypothesisDOI ↗